blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1257289

EP1257289 - IMMUNOTHERAPY USING INTERLEUKIN 13 RECEPTOR SUBUNIT ALPHA 2 [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  05.09.2003
Database last updated on 20.09.2024
Most recent event   Tooltip05.09.2003Withdrawal of applicationpublished on 22.10.2003  [2003/43]
Applicant(s)For all designated states
THE PENN STATE RESEARCH FOUNDATION
304 Old Main
University Park, PA 16802 / US
[2002/47]
Inventor(s)01 / DEBINSKI, Waldemar
231 Cedar Avenue
Hershey, PA 17033-1517 / US
 [2002/47]
Representative(s)Kupecz, Arpad
Octrooibureau Los en Stigter B.V.
P.O. Box 20052
1000 HB Amsterdam / NL
[N/P]
Former [2002/47]Kupecz, Arpad
Octrooibureau Los en Stigter B.V. Postbox 20052
1000 HB Amsterdam / NL
Application number, filing date01909106.508.02.2001
[2002/47]
WO2001US04384
Priority number, dateUS20000181000P08.02.2000         Original published format: US 181000 P
[2002/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO0158479
Date:16.08.2001
Language:EN
[2001/33]
Type: A1 Application with search report 
No.:EP1257289
Date:20.11.2002
Language:EN
The application published by WIPO in one of the EPO official languages on 16.08.2001 takes the place of the publication of the European patent application.
[2002/47]
Search report(s)International search report - published on:US16.08.2001
ClassificationIPC:A61K39/00, A61K39/395, A01N43/04, C07K1/00, C07K16/00
[2002/47]
CPC:
C07K14/7155 (EP,US); A61K39/001184 (EP,US); A61P25/00 (EP);
A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP);
C07K16/2866 (EP,US); A61K2039/505 (EP,US); A61K2039/5156 (EP,US);
A61K2039/53 (EP,US); A61K2039/545 (EP,US) (-)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   TR [2002/47]
Extension statesALNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
RONot yet paid
SINot yet paid
TitleGerman:IMMUNTHERAPIE UNTER VERWENDUNG DER ALPHA-UNTEREINHEIT DES INTERLEUKIN-13 REZEPTORS[2002/47]
English:IMMUNOTHERAPY USING INTERLEUKIN 13 RECEPTOR SUBUNIT ALPHA 2[2002/47]
French:UTILISATION DU RECEPTEUR DE L'INTERLEUKINE 13, SOUS-UNITE ALPHA 2, DANS L'IMMUNOTHERAPIE[2002/47]
Entry into regional phase09.09.2002National basic fee paid 
09.09.2002Search fee paid 
09.09.2002Designation fee(s) paid 
09.09.2002Examination fee paid 
Examination procedure06.08.2001Request for preliminary examination filed
International Preliminary Examining Authority: US
09.09.2002Examination requested  [2002/47]
01.09.2003Application withdrawn by applicant  [2003/43]
Fees paidRenewal fee
28.02.2003Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]US5710023  (COLLINS MARY [US], et al);
 [Y]US5827703  (DEBS ROBERT JAMES [US], et al);
 [Y]US5855866  (THORPE PHILIP E [US], et al);
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.